Viva Biotech Holdings
Viva Biotech Holdings Fundamental Analysis
Viva Biotech Holdings (VBIZF) shows weak financial fundamentals with a PE ratio of 33.35, profit margin of 9.38%, and ROE of 4.48%. The company generates $1.6B in annual revenue with weak year-over-year growth of -7.84%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 29.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze VBIZF's fundamental strength across five key dimensions:
Efficiency Score
WeakVBIZF struggles to generate sufficient returns from assets.
Valuation Score
ModerateVBIZF shows balanced valuation metrics.
Growth Score
WeakVBIZF faces weak or negative growth trends.
Financial Health Score
ExcellentVBIZF maintains a strong and stable balance sheet.
Profitability Score
WeakVBIZF struggles to sustain strong margins.
Key Financial Metrics
Is VBIZF Expensive or Cheap?
P/E Ratio
VBIZF trades at 33.35 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, VBIZF's PEG of 0.47 indicates potential undervaluation.
Price to Book
The market values Viva Biotech Holdings at 1.48 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.94 times EBITDA. This signals the market has high growth expectations.
How Well Does VBIZF Make Money?
Net Profit Margin
For every $100 in sales, Viva Biotech Holdings keeps $9.38 as profit after all expenses.
Operating Margin
Core operations generate 12.19 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $4.48 in profit for every $100 of shareholder equity.
ROA
Viva Biotech Holdings generates $2.50 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Viva Biotech Holdings produces operating cash flow of $304.38M, showing steady but balanced cash generation.
Free Cash Flow
Viva Biotech Holdings generates strong free cash flow of $185.61M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.09 in free cash annually.
FCF Yield
VBIZF converts 4.31% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
33.35
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.47
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.48
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.71
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.30
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.76
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How VBIZF Stacks Against Its Sector Peers
| Metric | VBIZF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 33.35 | 29.45 | Worse (Expensive) |
| ROE | 4.48% | 779.00% | Weak |
| Net Margin | 9.38% | -24936.00% (disorted) | Weak |
| Debt/Equity | 0.30 | 0.26 | Neutral |
| Current Ratio | 1.76 | 4.65 | Neutral |
| ROA | 2.50% | -19344.00% (disorted) | Weak |
VBIZF outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Viva Biotech Holdings's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
325.11%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-56.50%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
461.89%
Industry Style: Defensive, Growth, Innovation
High Growth